Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) provide greater weight reduction and better metabolic control compared to GLP-1 receptor mono-agonists.
If you are not achieving sufficient weight loss with a GLP-1 medication like semaglutide, switching to a dual GIP/GLP-1 agonist like tirzepatide may offer greater benefits. Clinical trials show that tirzepatide can lead to even more significant weight loss compared to existing GLP-1 drugs. This makes it a strong option for those who need more aggressive treatment.
GIP/GLP-1 dual-agonism appear to provide better metabolic control and greater weight reduction compared with GLP-1-R mono-agonism.
Why this rating
Supported by direct comparisons in Phase 3 trials (e.g., STEP 2 comparing semaglutide to liraglutide, and SURMOUNT trials showing high efficacy of tirzepatide).
Source
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först et al. · Diabetes Obesity and Metabolism · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →